UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

Cancer chemotherapy and pharmacology, 2015-04, Vol.75 (4), p.851-859

2015

Volltextzugriff (PDF)

Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study

Clinical lymphoma, myeloma and leukemia, 2015-07, Vol.15 (7), p.443-449

2015

Volltextzugriff (PDF)

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Blood, 2008-06, Vol.111 (11), p.5350-5358

2008

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies

Journal of clinical oncology, 2000-01, Vol.18 (1), p.178-186

2000

Volltextzugriff (PDF)

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2001-10, Vol.48 (4), p.269-274

2001

Volltextzugriff (PDF)

Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2585-2585

2014

Volltextzugriff (PDF)

Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2529-2529

2015

Volltextzugriff (PDF)

Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.5441-5441

2014

Volltextzugriff (PDF)

Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A16-A16

2013

Volltextzugriff (PDF)

Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2531-2531

2015

Volltextzugriff (PDF)

A Phase I Study of Raltitrexed, an Antifolate Thymidylate Synthase Inhibitor, in Adult Patients with Advanced Solid Tumors

Clinical cancer research, 1999-09, Vol.5 (9), p.2381-2391

1999

Volltextzugriff (PDF)

Abstract LB-204: Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.LB-204-LB-204

2011

Volltextzugriff (PDF)

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2532-2532

2014

Volltextzugriff (PDF)

Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.7029-7029

2014

Volltextzugriff (PDF)

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Commentary

Blood, 2008, Vol.111 (11)

2008

Volltextzugriff (PDF)

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, in combination with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - results of a phase I dose escalation study

Clinical lymphoma, myeloma and leukemia, 2015-03, Vol.15 (7), p.443-449

2015

Volltextzugriff (PDF)

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

Journal of clinical oncology, 1998-09, Vol.16 (9), p.3007-3015

1998

Volltextzugriff (PDF)

Clinical use of thymidine as a rescue agent from methotrexate toxicity

Investigational new drugs, 1991-08, Vol.9 (3), p.281-290

1991

Volltextzugriff (PDF)

Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia

Journal of clinical oncology, 1998-07, Vol.16 (7), p.2313-2320

1998

Volltextzugriff (PDF)

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction

Journal of clinical oncology, 1997-05, Vol.15 (5), p.2125-2134

1997

Volltextzugriff (PDF)

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma

Journal of clinical oncology, 1991-10, Vol.9 (10), p.1811-1820

1991

Volltextzugriff (PDF)

A pilot study of γ-1b-interferon in combination with fluorouracil, leucovorin, and α-2a-interferon

Clinical cancer research, 1997-07, Vol.3 (7), p.1125-1134

1997

Volltextzugriff (PDF)

Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia

Leukemia & lymphoma, 1991, Vol.5 (S1), p.119-122

1991

Volltextzugriff (PDF)

Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia

Nature communications, 2018-04, Vol.9 (1), p.1340-9, Article 1340

2018

Volltextzugriff (PDF)

Student diversity and student voice conceptualisations in five European countries: Implications for including all students in schools

European educational research journal EERJ, 2022-03, Vol.21 (2), p.355-376

2022

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(28)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Humans
(14)
Science & Technology
(12)
Female
(11)
Life Sciences & Biomedicine
(11)
Male
(11)
Adult
(10)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Middle Aged
(9)
Pharmacology. Drug Treatments
(9)
Aged
(8)
Oncology
(8)
Antineoplastic Agents
(6)
Antineoplastic Agents - Adverse Effects
(5)
Dose-Response Relationship, Drug
(5)
Administration, Oral
(4)
Chemotherapy
(4)
Neoplasms - Drug Therapy
(4)
Aged, 80 And Over
(3)
Antineoplastic Agents - Administration & Dosage
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

Oral Debio1143 (AT406), an Antagonist of Inhibitor of Apoptosis Proteins, Combined With Daunorubicin and Cytarabine in Patients With Poor-Risk Acute Myeloid Leukemia—Results of a Phase I Dose-Escalation Study

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies

Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors

Clinical pharmacokinetic (PK)/pharmacodynamic (PD) model for Debio 1143, a novel antagonist of IAPs in cancer treatment

Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma

Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models

Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells

Phase I dose-escalation study with extended daily administration of Debio1143, an oral inhibitor of apoptosis protein inhibitor, in patients with solid tumors

A Phase I Study of Raltitrexed, an Antifolate Thymidylate Synthase Inhibitor, in Adult Patients with Advanced Solid Tumors

Abstract LB-204: Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia

First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results

Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML)

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma. Commentary

Oral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, in combination with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia - results of a phase I dose escalation study

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients

Clinical use of thymidine as a rescue agent from methotrexate toxicity

Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphocytic leukemia

Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction

A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma

A pilot study of γ-1b-interferon in combination with fluorouracil, leucovorin, and α-2a-interferon

Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia

Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia

Student diversity and student voice conceptualisations in five European countries: Implications for including all students in schools

Suchergebnisse filtern